Wockhardt Limited has announced that the Indian drug regulator has approved its new oral antibiotic Miqnaf for treating community-acquired bacterial pneumonia. This approval follows a favorable recommendation from the Subject Expert Committee of the Central Drugs Standard Control Organization. Miqnaf is designed as a short, once-a-day treatment that addresses antibiotic resistance issues in pneumonia cases. Wockhardt plans to launch Miqnaf in the Indian market in the coming months.
Wockhardt Limited has informed the Exchange regarding a press release dated January 02, 2025, titled "Indian Drug Regulator Approves Wockhardt's New Generation Oral Antibiotic Miqnaf? (Nafithromycin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)."